Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in ...

Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Jon Baptiste revealed that his wife Suleika Jaouad is "doing great" amid her cancer going into remission again during an ...

J&J will now pick up almost the full tab for the phase 3 trial, and in return Nanobiotix will see the potential milestone payments that could come its way drop $105 million to $2.6 billion. Shares in ...

An 85-year-old who credits the Lingen Davies Cancer Centre with saving his life is preparing for a final trip to his beloved ...

Dr Toral Vaidya, a New York City based board certified dermatologist, recently shared signs and symptoms of skin cancer she ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

InflaRx (NASDAQ:IFRX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.27) ...

A research team led by Prof. JIANG Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – ...